JP2024514009A5 - - Google Patents
Info
- Publication number
- JP2024514009A5 JP2024514009A5 JP2023563841A JP2023563841A JP2024514009A5 JP 2024514009 A5 JP2024514009 A5 JP 2024514009A5 JP 2023563841 A JP2023563841 A JP 2023563841A JP 2023563841 A JP2023563841 A JP 2023563841A JP 2024514009 A5 JP2024514009 A5 JP 2024514009A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- nhc
- heteroaryl
- cycloalkyl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024199756A JP2025015696A (ja) | 2021-04-21 | 2024-11-15 | カルボキシ－ベンズイミダゾールｇｌｐ－１ｒ調節化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163177778P | 2021-04-21 | 2021-04-21 | |
| US63/177,778 | 2021-04-21 | ||
| US202163286475P | 2021-12-06 | 2021-12-06 | |
| US63/286,475 | 2021-12-06 | ||
| PCT/US2022/025364 WO2022225941A1 (en) | 2021-04-21 | 2022-04-19 | Carboxy-benzimidazole glp-1r modulating compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024199756A Division JP2025015696A (ja) | 2021-04-21 | 2024-11-15 | カルボキシ－ベンズイミダゾールｇｌｐ－１ｒ調節化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024514009A JP2024514009A (ja) | 2024-03-27 |
| JP2024514009A5 true JP2024514009A5 (https=) | 2024-04-15 |
| JP7600433B2 JP7600433B2 (ja) | 2024-12-16 |
Family
ID=81654570
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563841A Active JP7600433B2 (ja) | 2021-04-21 | 2022-04-19 | カルボキシ－ベンズイミダゾールｇｌｐ－１ｒ調節化合物 |
| JP2024199756A Pending JP2025015696A (ja) | 2021-04-21 | 2024-11-15 | カルボキシ－ベンズイミダゾールｇｌｐ－１ｒ調節化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024199756A Pending JP2025015696A (ja) | 2021-04-21 | 2024-11-15 | カルボキシ－ベンズイミダゾールｇｌｐ－１ｒ調節化合物 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11858918B2 (https=) |
| EP (2) | EP4271672B1 (https=) |
| JP (2) | JP7600433B2 (https=) |
| KR (1) | KR20230173708A (https=) |
| AU (2) | AU2022263410B2 (https=) |
| BR (1) | BR112023021561A2 (https=) |
| CA (1) | CA3216163A1 (https=) |
| CL (1) | CL2023003119A1 (https=) |
| CO (1) | CO2023013757A2 (https=) |
| CR (1) | CR20230495A (https=) |
| DK (1) | DK4271672T3 (https=) |
| DO (1) | DOP2023000232A (https=) |
| FI (1) | FI4271672T3 (https=) |
| HR (1) | HRP20260177T1 (https=) |
| IL (1) | IL306110A (https=) |
| LT (1) | LT4271672T (https=) |
| MX (1) | MX2023012418A (https=) |
| PE (1) | PE20240362A1 (https=) |
| PH (1) | PH12023552860A1 (https=) |
| PL (1) | PL4271672T3 (https=) |
| PT (1) | PT4271672T (https=) |
| SI (1) | SI4271672T1 (https=) |
| TW (1) | TWI828119B (https=) |
| WO (1) | WO2022225941A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4048664A1 (en) | 2019-10-25 | 2022-08-31 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| ES3016132T3 (en) | 2020-01-29 | 2025-05-08 | Gilead Sciences Inc | Glp-1r modulating compounds |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| WO2022192428A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| EP4304712A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| IL306110A (en) | 2021-04-21 | 2023-11-01 | Gilead Sciences Inc | Carboxy-benzimidazole glp-1r modulating compounds |
| PT4408840T (pt) | 2021-09-27 | 2025-10-07 | Terns Pharmaceuticals Inc | Ácidos benzimidazolocarboxílicos como agonistas de glp-1r |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| CN119095843A (zh) | 2022-02-23 | 2024-12-06 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| EP4592285A1 (en) | 2022-09-22 | 2025-07-30 | Shionogi & Co., Ltd. | Fused ring compound having glp-1 receptor agonist effect |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| KR20250085816A (ko) | 2022-11-16 | 2025-06-12 | 일라이 릴리 앤드 캄파니 | 글루카곤-유사 펩티드 1 수용체 효능제 |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| WO2024212742A1 (zh) * | 2023-04-10 | 2024-10-17 | 上海研健新药研发有限公司 | 一种glp-1r激动剂，其制备方法和应用 |
| EP4731245A1 (en) * | 2023-06-23 | 2026-04-29 | Merck Sharp & Dohme LLC | Use of a long-acting oxyntomodulin derivative for treament of fatty liver disease |
| WO2025021048A1 (zh) * | 2023-07-21 | 2025-01-30 | 石药集团中奇制药技术（石家庄）有限公司 | 一类多环化合物及其用途 |
| CN120981457A (zh) | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| WO2026033382A1 (en) * | 2024-08-07 | 2026-02-12 | Pfizer Inc. | Heterocyclic glp-1r modulators |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6235755B1 (en) | 1998-08-07 | 2001-05-22 | Applied Research Systems Ars Holding N.A. | FSH mimetics for the treatment of infertility |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| WO2003026587A2 (en) | 2001-09-26 | 2003-04-03 | Bristol-Myers Squibb Company | Compounds useful for treating hepatitus c virus |
| US7329680B2 (en) | 2003-04-30 | 2008-02-12 | The Institute For Pharmaceutical Discovery, Llc | Heterocycle substituted carboxylic acids |
| AR044152A1 (es) | 2003-05-09 | 2005-08-24 | Bayer Corp | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
| EP1633710A1 (en) | 2003-06-02 | 2006-03-15 | Abbott Laboratories | Isoindolin-1-one compounds as kinase inhibitors |
| WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用 |
| JP2008520692A (ja) | 2004-11-18 | 2008-06-19 | ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー | 複素環置換カルボン酸 |
| EP1838690A2 (en) | 2004-12-21 | 2007-10-03 | Devgen N.V. | Compounds with kv4 ion channel activity |
| EP1940786B1 (en) | 2005-09-16 | 2010-08-18 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis c |
| CA2646755A1 (en) | 2006-03-31 | 2007-10-11 | Astrazeneca Ab | Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators |
| WO2008033455A2 (en) | 2006-09-13 | 2008-03-20 | The Institutes For Pharmaceutical Discovery, Llc | Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors |
| EA018225B1 (ru) | 2008-03-07 | 2013-06-28 | Транстек Фарма, Инк. | Соединения оксадиазоантрацена для лечения диабета |
| WO2010029300A1 (en) | 2008-09-12 | 2010-03-18 | Biolipox Ab | Bis aromatic compounds for use in the treatment of inflammation |
| WO2010029299A1 (en) | 2008-09-12 | 2010-03-18 | Biolipox Ab | Pyrimidinone derivaties for use as medicaments |
| WO2010046780A2 (en) | 2008-10-22 | 2010-04-29 | Institut Pasteur Korea | Anti viral compounds |
| WO2011143365A1 (en) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
| JP2013530963A (ja) | 2010-06-09 | 2013-08-01 | レセプトス インコーポレイテッド | 新規のｇｌｐ−１受容体安定化薬および調節薬 |
| WO2011163355A1 (en) | 2010-06-24 | 2011-12-29 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors |
| JP2014525932A (ja) | 2011-08-15 | 2014-10-02 | インターミューン， インコーポレイテッド | リゾホスファチド酸レセプターアンタゴニスト |
| WO2013056679A1 (en) | 2011-10-21 | 2013-04-25 | Beijing Hanmi Pharmaceutical Co., Ltd | Novel heteroaryl-amino derivatives |
| BR112014013925B1 (pt) | 2011-12-12 | 2022-02-22 | Receptos Llc | Compostos moduladores do receptor de glp-1 e composição e combinação farmacêutica compreendendo os ditos compostos |
| BR112014030940B1 (pt) | 2012-06-11 | 2022-09-06 | UCB Biopharma SRL | Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos |
| US10011585B2 (en) | 2014-07-28 | 2018-07-03 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| KR20160066490A (ko) | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
| NZ734082A (en) | 2015-01-20 | 2019-01-25 | Boehringer Ingelheim Animal Health Usa Inc | Anthelmintic compounds, compositions and method of using thereof |
| US20170035881A1 (en) | 2015-10-19 | 2017-02-09 | Acerta Pharma B.V. | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor |
| PL3429591T3 (pl) | 2016-03-16 | 2023-07-17 | Kura Oncology, Inc. | Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania |
| KR102354068B1 (ko) | 2016-03-30 | 2022-01-25 | 이시하라 산교 가부시끼가이샤 | 피리다지논계 화합물 또는 그의 염, 및 그것들을 함유하는 제초제 |
| KR102314286B1 (ko) * | 2016-12-16 | 2021-10-21 | 화이자 인코포레이티드 | Glp-1 수용체 작용제 및 이의 용도 |
| CN110799190B (zh) | 2017-03-27 | 2024-04-19 | 卡都瑞恩医药有限公司 | 杂环化合物 |
| EP3681499A4 (en) | 2017-09-13 | 2021-04-21 | D.E. Shaw Research, LLC | CONNECTIONS AS RAS INHIBITORS AND THEIR USE |
| MX2020008387A (es) | 2018-05-08 | 2020-12-11 | Vtv Therapeutics Llc | Usos terapeuticos de agonistas glp1r. |
| US10934279B2 (en) | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| DK3806855T5 (da) | 2018-06-15 | 2023-05-22 | Pfizer | GLP-1-receptoragonister og anvendelser deraf |
| US11945803B2 (en) | 2018-08-07 | 2024-04-02 | Tosk, Inc. | Modulators of RAS GTPase |
| MA54555A (fr) | 2018-11-22 | 2021-09-29 | Qilu Regor Therapeutics Inc | Agonistes de glp-1r et leurs utilisations |
| EP3953344A4 (en) * | 2019-04-12 | 2023-08-09 | Qilu Regor Therapeutics Inc. | GLP-IR AGONISTS AND THEIR USES |
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| CN112294760B (zh) | 2019-07-26 | 2025-12-12 | 宁波新致生物科技有限公司 | 一种液体制剂及其应用 |
| WO2021018023A1 (zh) | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
| CN112409331B (zh) | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| EP4048664A1 (en) * | 2019-10-25 | 2022-08-31 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| KR102841983B1 (ko) | 2019-11-04 | 2025-08-04 | 주식회사 엘지화학 | 광변조 디바이스의 제조 방법 |
| WO2021096284A1 (ko) | 2019-11-15 | 2021-05-20 | 일동제약(주) | Glp-1 수용체 작용제 및 이의 용도 |
| CN114761395B (zh) * | 2019-12-02 | 2024-11-15 | 现代药品株式会社 | Glp-1受体激动剂 |
| ES3016132T3 (en) | 2020-01-29 | 2025-05-08 | Gilead Sciences Inc | Glp-1r modulating compounds |
| HRP20241159T1 (hr) | 2020-02-07 | 2024-12-06 | Gasherbrum Bio, Inc. | Heterociklički agonisti za glp-1 |
| JP7836762B2 (ja) | 2020-02-13 | 2026-03-27 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| IL296336A (en) | 2020-03-18 | 2022-11-01 | Lg Chemical Ltd | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| JP2021155415A (ja) | 2020-03-27 | 2021-10-07 | ファイザー・インク | ２−［（４−｛６−［（４−シアノ−２−フルオロベンジル）オキシ］ピリジン−２−イル｝ピペリジン−１−イル）メチル］−１−［（２ｓ）−オキセタン−２−イルメチル］−１ｈ−ベンゾイミダゾール−６−カルボン酸またはその薬学的な塩を用いた２型糖尿病、または肥満、または過体重の治療 |
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| CN113493447B (zh) | 2020-04-03 | 2024-06-11 | 轩竹(北京)医药科技有限公司 | Glp-1受体激动剂 |
| JP7702973B2 (ja) | 2020-05-27 | 2025-07-04 | キル・レガー・セラピューティクス・インコーポレーテッド | Ｇｌｐ－１ｒアゴニストの塩及び結晶形態、並びにそれらの使用 |
| MX2022015026A (es) | 2020-06-04 | 2023-01-04 | Hangzhou Sciwind Biosciences Co Ltd | Compuesto heteroaromatico de imidazol de cinco miembros y uso del mismo. |
| CN113816948B (zh) | 2020-06-19 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
| WO2022031994A1 (en) | 2020-08-06 | 2022-02-10 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
| CA3192601A1 (en) | 2020-08-21 | 2022-02-24 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| WO2022068772A1 (zh) | 2020-09-29 | 2022-04-07 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| WO2022078152A1 (zh) | 2020-10-12 | 2022-04-21 | 杭州中美华东制药有限公司 | 苯并咪唑酮类glp-1受体激动剂及其用途 |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| MX2023006186A (es) | 2020-11-27 | 2023-08-07 | Shenzhen Salubris Pharm Co Ltd | Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo. |
| KR20230155452A (ko) | 2021-03-09 | 2023-11-10 | 바스프 에스이 | 트리시클릭 살충 화합물 |
| EP4304712A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| WO2022192428A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| WO2022216094A1 (ko) | 2021-04-08 | 2022-10-13 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
| IL306110A (en) | 2021-04-21 | 2023-11-01 | Gilead Sciences Inc | Carboxy-benzimidazole glp-1r modulating compounds |
| TW202304500A (zh) | 2021-04-21 | 2023-02-01 | 瑞士商諾華公司 | 升糖素樣肽化合物 |
| ES3025032T7 (en) | 2021-04-21 | 2026-04-24 | Gilead Sciences Inc | Carboxy-benzimidazole glp-1r modulating compounds |
| IL309235A (en) | 2021-06-24 | 2024-02-01 | Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd | Glp-1 receptor agonist and composition and use thereof |
| CN113480534B (zh) | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
| EP4441038A1 (en) | 2021-11-30 | 2024-10-09 | Kura Oncology, Inc. | Macrocyclic compounds having farnesyltransferase inhibitory activity |
-
2022
- 2022-04-19 IL IL306110A patent/IL306110A/en unknown
- 2022-04-19 LT LTEPPCT/US2022/025364T patent/LT4271672T/lt unknown
- 2022-04-19 PT PT227238516T patent/PT4271672T/pt unknown
- 2022-04-19 EP EP22723851.6A patent/EP4271672B1/en active Active
- 2022-04-19 WO PCT/US2022/025364 patent/WO2022225941A1/en not_active Ceased
- 2022-04-19 US US17/724,212 patent/US11858918B2/en active Active
- 2022-04-19 CA CA3216163A patent/CA3216163A1/en active Pending
- 2022-04-19 KR KR1020237039911A patent/KR20230173708A/ko active Pending
- 2022-04-19 PH PH1/2023/552860A patent/PH12023552860A1/en unknown
- 2022-04-19 MX MX2023012418A patent/MX2023012418A/es unknown
- 2022-04-19 EP EP25207471.1A patent/EP4691554A3/en active Pending
- 2022-04-19 BR BR112023021561A patent/BR112023021561A2/pt unknown
- 2022-04-19 AU AU2022263410A patent/AU2022263410B2/en active Active
- 2022-04-19 FI FIEP22723851.6T patent/FI4271672T3/fi active
- 2022-04-19 SI SI202230242T patent/SI4271672T1/sl unknown
- 2022-04-19 HR HRP20260177TT patent/HRP20260177T1/hr unknown
- 2022-04-19 DK DK22723851.6T patent/DK4271672T3/da active
- 2022-04-19 JP JP2023563841A patent/JP7600433B2/ja active Active
- 2022-04-19 PE PE2023002895A patent/PE20240362A1/es unknown
- 2022-04-19 CR CR20230495A patent/CR20230495A/es unknown
- 2022-04-19 PL PL22723851.6T patent/PL4271672T3/pl unknown
- 2022-04-20 TW TW111114936A patent/TWI828119B/zh active
-
2023
- 2023-10-19 CO CONC2023/0013757A patent/CO2023013757A2/es unknown
- 2023-10-19 DO DO2023000232A patent/DOP2023000232A/es unknown
- 2023-10-19 CL CL2023003119A patent/CL2023003119A1/es unknown
- 2023-10-27 US US18/496,137 patent/US12570642B2/en active Active
-
2024
- 2024-10-08 AU AU2024227155A patent/AU2024227155A1/en active Pending
- 2024-11-15 JP JP2024199756A patent/JP2025015696A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024514009A5 (https=) | ||
| JP2024514010A5 (https=) | ||
| HRP20250415T1 (hr) | Modulirajući spojevi karboksi-benzimidazola glp-1r | |
| JP2023546054A5 (https=) | ||
| JP2023540609A5 (https=) | ||
| JP2023540558A5 (https=) | ||
| JP2023546055A5 (https=) | ||
| JP2023515404A5 (https=) | ||
| US10160743B2 (en) | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | |
| ES2713566T3 (es) | Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II | |
| JP2019069940A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| US20120046305A1 (en) | Methods and compositions for treating respiratory disorders | |
| JP2019517478A5 (https=) | ||
| JP2018530571A5 (https=) | ||
| TWI224102B (en) | Serotonergic agents | |
| JP2007519753A5 (https=) | ||
| KR20090088854A (ko) | 2-6-(3-아미노-피페리딘-엘-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸-4-플루오로-벤조니트릴의 용도 | |
| RU2011103741A (ru) | Композиции и способы лечения заболевания сетчатки | |
| KR20110103968A (ko) | 유기 화합물의 염 형태 | |
| TWI842924B (zh) | Gpr119致效劑及dpp-4抑制劑的藥物組合及藥物套組 | |
| AU2011237421B2 (en) | Inverse agonists and neutral antagonists for the TSH receptor | |
| WO2025011664A1 (zh) | Glp-1r激动剂的制剂及其制备方法 | |
| JP2023500685A5 (https=) | ||
| CN1537016A (zh) | 精神神经疾病治疗药 | |
| JP2017523211A (ja) | 新規化合物およびそれを用いてｉｌ−１ｒ媒介性の疾患または障害を処置するかまたは寛解させる方法 |